. Author manuscript; available in PMC: 2019 Oct 24.

Published in final edited form as: J AIDS HIV Res. 2017 Jan 31;9(1):17–30. doi: 10.5897/JAHR2016.0406

Table 6.

Resistance mutations by ARV drug class.

Participant	Protease inhibitor mutations	NRTI mutations	NNRTI mutations
1	L10F, M46I, Q58E, A71I, I84V^*	M41L, D67G, T69N, K70N, V75I, M184V^*, T215F	A98G, V179E, Y181C^, G190A^
2	I50L^*	M41L, D67G, V75I, M184V/I^*, K70Q, T215F	Y188L^*
3	Q58E, V82M	D67G, M184V^*, T69D, K70R, K219Q	A98G, Y181C^, G190A^, K101E
4	-	D67G, K70R, T215I, T219E	G190A^*, E138G
5	-	-	A98G, Y181C^*, V90I
6	-	-	-
7	-	-	K101H/Q
8	-	M184V^*	K103N^, E138A*
9	-
10	-	D67G, M184V^*, K70G	A98G, Y318F
11	-	T69N	Y181C^, G190A^, K101E, V90I
12	-	-	Y181C^*, K103T, H221Y
13	-	V75I, M184V^, K65R^, D67N, Y115F, K219E	Y181C^*, V108I
14	A71T	M41L, T69N, K70R, D67N, T215L, K219E	A98G, Y181C^, K103N^, K238T
15	-	M184V^*, K70E/G/R, D67N	V90I, K103N^*, Y318F
16	-	M184I/V^*	G190A^*
17	L90M	T69N	-
18	-	M41L, M184V^*, T215C/Y	K103N^*, Y318F, E138Q
19	-	M41L, V75I, M184V^*, T215F/Y	E138A, H221Y, Y181I
20	A71I/T, N88S^*, L10V	T69A/N, M184V^*, T215F, K70R, K219E, D67S, L74V	K103N^, L100I^, M230L^*
21	_	T69D/N	Y181C^, G190A^
22	-	T69N	Y181C^*
23		-	-
24	M46I, I50L^, L10V, L33F, I47V*, A71V, G73C/S, V82A^#	M184V^*, T215F	A98G, G190A^, K101E, E138A*
25	M46I	-	Y181C^*, E138G, H221Y
26	I50L^*, V82M, V32I^#, L24I, N83D	M41L, K70N, V75I, M184V^*, T215Y	H221Y, K103S^, V106M^, F227L^#
27	V82M, A71V, L24I, K43T, F53L, I54V^#, T74P	M184V^*, A62V, 69deIT, V75T, Q151M	Y188L^*
28	-	-	K103N^, E138A*
Without mutations, n(%)	18(64)	8(29)	4(14%)

high level resistance;

intermediate level resistance;

Italics-low level resistance; PI, protease inhibitor; NNRTI, non-nucleotide reverse transcriptase inhibitors; NRTI, nucleot/side reverse transcriptase inhibitors.